@article{6114a427110646c69d2461fca0150205,
title = "Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study",
keywords = "B-cell neoplasms, clinical results in lymphoma, immunotherapeutic approaches, rituximab, treatment patterns",
author = "Link, {Brian K.} and Day, {Bann mo} and Xiaolei Zhou and Zelenetz, {Andrew D.} and Dawson, {Keith L.} and Cerhan, {James R.} and Flowers, {Christopher R.} and Friedberg, {Jonathan W.}",
note = "Funding Information: This study was funded by Genentech Inc. (South San Francisco, CA, USA). Editorial support was provided by Lynda McEvoy of Gardiner-Caldwell Communications (Macclesfield, UK), funded by Genentech Inc. Dr Link had full access to all the data in the study and takes responsibility for the integrity for the data and the accuracy of the data analysis. Dr Day and Dr Zhou conducted the statistical analysis.",
year = "2019",
month = feb,
doi = "10.1111/bjh.15149",
language = "English (US)",
volume = "184",
pages = "660--663",
journal = "British journal of haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",
}